Premium
TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES
Author(s) -
Cheah C. Y,
Jurczak W,
Lasica M,
Wickham N,
Wróbel T,
Walewski J,
Yannakou C. K,
Cheung S,
Lewis K. L,
DługoszDanecka M,
Giannopoulos K,
Miskin H. P,
Tang J.P,
Normant E,
O'Connor O. A,
Ricart A. D,
Tam C. S
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.148_2880
Subject(s) - medicine , bruton's tyrosine kinase , chemoimmunotherapy , refractory (planetary science) , gastroenterology , cohort , progressive disease , rituximab , oncology , surgery , lymphoma , tyrosine kinase , chemotherapy , receptor , physics , astrobiology